CEL-SCI CORPORATION Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CEL-SCI CORPORATION (CVM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.43 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-12-31 was -$4.68M.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-12-31 was -$124.06K.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-12-31 was -$904.29K.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-12-31 was -$4.65M, a 543.41% decline year-over-year.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $6.22M, a 949.10% increase from fiscal 2024.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $592.44K.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$18.53M.
- CEL-SCI CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$13.39M, a 165.14% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.43M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$9.06M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$4.68M 10-Q · filed 2026-02-17 | |||
| 2025-09-30 | $6.22M 10-K · filed 2025-12-29 | |||
| 2025-06-30 | -$2.95M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$2.81M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$124.06K 10-Q · filed 2026-02-17 | |||
| 2024-09-30 | $592.44K 10-K · filed 2025-12-29 | |||
| 2024-06-30 | -$3.76M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $1.16M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$904.29K 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | -$18.53M 10-K · filed 2025-01-13 | |||
| 2023-06-30 | -$17.54M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$12.63M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$4.65M 10-Q · filed 2024-02-14 | |||
| 2022-09-30 | -$13.39M 10-K · filed 2023-12-21 | |||
| 2022-06-30 | -$7.99M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$1.78M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $1.05M 10-Q · filed 2023-02-14 | |||
| 2021-09-30 | $20.55M 10-K · filed 2022-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |